Deltex Medical Group Plc engages in manufacturing and sale of advanced haemodynamic monitoring technologies. The company is headquartered in Chichester, West Sussex and currently employs 37 full-time employees. The firm develops, manufactures and distributes a hemodynamic monitoring technology. The firm's TrueVue platform offers three monitoring technologies, such as Oesophageal Doppler Monitoring (ODM+), Pulse Pressure Waveform Analysis (PPWA) and High Definition Impedance CardioGraphy (HD-ICG). Its ODM+ is a fluid management and cardiac output monitoring technology to directly measure both flow and pressure in adults and pediatrics. HD-ICG provides continuous and sensitive measurements of cardiac output and other hemodynamic parameters. The system is stabilized using HD-Z signal filter technology. HD-ICG disposable electrodes are placed on the neck and chest. PPWA uses the researched pulse pressure wave algorithm, which is available to derive hemodynamic parameters, calibrated from the Doppler. Its applications include surgery, acute kidney injury, enhanced recovery, paediatric, and COVID-19 critical care.
Follow-Up Questions
Who is the CEO of Deltex Medical Group PLC?
Ms. Natalie Wettler is the Chief Executive Officer of Deltex Medical Group PLC, joining the firm since 2020.
What is the price performance of DTXMF stock?
The current price of DTXMF is $0, it has decreased 0% in the last trading day.
What are the primary business themes or industries for Deltex Medical Group PLC?
Deltex Medical Group PLC belongs to Health Care industry and the sector is Health Care
What is Deltex Medical Group PLC market cap?
Deltex Medical Group PLC's current market cap is $NaN
